Compare Apple Inc (AAPL) vs Abeona Therapeutics Inc (ABEO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apple Inc vs Abeona Therapeutics Inc — how do they compare? Apple Inc trades at $305.17 (market cap $4.50T), while Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M). The key difference: Apple Inc is far larger — about 10605× Abeona Therapeutics Inc's market cap, and Apple Inc pays a 0.35% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| AAPL | ABEO | |
|---|---|---|
Market Cap | $4.50T | $424.33M |
Volume | 100,358,844 | — |
Sector | Technology | Health |
52-Week High | $340.08 | $7.45 |
52-Week Low | $224.90 | $4.17 |
Enterprise Value | $4.52T | $279.23M |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AAPL trades at $308.26, down 1.62% on the day, with a bearish technical signal but strong fundamentals including a 26.91% net margin and three consecutive quarterly EPS beats. Recent news highlights AI potential via 2.5 billion devices and a Gemini partnership, though store closures and union disputes present headwinds.
The outlook balances robust earnings growth and cash flow against high valuation multiples and technical weakness. Upside to the $337.63 consensus target exists if AI initiatives accelerate, but competition and macroeconomic pressures remain key risks for investors.
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Apple Inc
Apple Inc. designs, manufactures, and markets personal computers and related personal computing and mobile communication devices along with a variety of related software, services, peripherals, and networking solutions. Apple sells its products worldwide through its online stores, its retail stores, its direct sales force, third-party wholesalers, and resellers.
Read more on AAPL →About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →
